All In Biotech

Drug Trial Radar · NCT07413952

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Efficacy and Safety of Limertinib (ASK120067) Combined With Radiotherapy as First-Line Treatment in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases: A Single-Arm, Multicenter, Prospective Phase II Study

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients. Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity. The potential synergistic effect of limertinib combined with radiotherapy warrants further investigation. This prospective, multicenter, single-arm phase II study aims to evaluate the efficacy and safety of first-line limertinib combined with radiotherapy in this patient population.

Conditions

  • NSCLC

Interventions

  • Limertinib Plus RadiotherapyDrug

    Limertinib Plus Radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intracranial progression-free survival (iPFS)Time frame: Up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.